CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy

Clinical Infectious Diseases

Volumn 47, Issue 8, 2008, Pages 1093-1101

  Khanna, Nina ^a   Opravil, Milos ^b   Furrer, Hansjakob ^c   Cavassini, Matthias ^d   Vernazza, Pietro ^e   Bernasconi, Enos ^f   Weber, Rainer ^b   Hirschel, Bernard ^g   Battegay, Manuel ^a   Kaufmann, Gilbert R ^a   Battegay, M ^d   Bernasconi, E ^d   Boni J ^d   Bucher, H C ^d   Burgisser P ^d   Calmy, A ^d   Cattacin, S ^d   Cavassini, M ^d   Dubs, R ^d   Egger, M ^d   Elzi, L ^d   Erb, P ^d   Fischer, M ^d   Flepp, M ^d   Fontana, A ^d   Francioli, P ^d   Furrer, H ^h   Fux, C ^h   Gorgievski, M ^h   Gunthard H ^h   Hirsch, H ⁱ   Hirschel, B ⁱ   Hosli I ⁱ   Kahlert, C ⁱ   Kaiser, L ⁱ   Karrer, U ⁱ   Kind, C ⁱ   Klimkait, T ⁱ   Ledergerber, B ⁱ   Martinetti, G ⁱ   Martinez, B ⁱ   Muller N ⁱ   Nadal, D ⁱ   Opravil, M ⁱ   Paccaud, F ⁱ   Pantaleo, G ⁱ   Rauch, A ⁱ   Regenass, S ⁱ   Rickenbach, M ⁱ   Rudin, C ^h   Schmid, P ^h   Schultze, D ^h   Schupbach J ^h   Speck, R ^h   Taffe P ^h   Tarr, P ^h   Telenti, A ^h   Trkola, A ^h   Vernazza, P ^h   Weber, R ^h   Yerly, S ^h   more..

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^f REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^g UNIVERSITY HOSPITAL   (Switzerland)

^h Scientific Board ^*

ⁱ Data Center

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; EFAVIRENZ; INDINAVIR; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CONTROL GROUP; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; RNA VIRUS; SEROLOGY; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RNA, VIRAL; SWITZERLAND; VIRAL LOAD;

EID: 53349171968     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/592113     Document Type: Article

References (34)

1. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 1997; 315:1194-9.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
3. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-29.
4. Battegay M, Nuesch R, Hirschel B, Kaufmann GR. Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect Dis 2006; 6:280-7.
5. Kaufmann GR, Perrin L, Pantaleo G, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med 2003; 163:2187-95.
6. Hunt PW, Deeks SG, Rodriguez B, et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 2003; 17:1907-15.
7. Wood E, Yip B, Hogg RS, et al. Full suppression of viral load is needed to achieve an optimal CD4 cell count response among patients on triple drug antiretroviral therapy. AIDS 2000; 14:1955-60.
8. Kaufmann GR, Bloch M, Finlayson R, Zaunders J, Smith D, Cooper DA. The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy. AIDS 2002; 16:359-67.
9. Huttner AC, Kaufmann GR, Battegay M, Weber R, Opravil M. Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy. AIDS 2007; 21:939-46.
10. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350:1850-61.
11. Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2293-303.
12. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004; 292:251-65.
13. Gazzard B. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005). HIV Med 2005; 6(Suppl 2):1-61.
14. Vo TT, Ledergerber B, Keiser O, et al. Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study. J Infect Dis 2008; 197:1685-94.
15. Barrios A, Negredo E, Domingo P, et al. Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial. Antivir Ther 2005; 10:825-32.
16. Scott JD. Simplifying the treatment of HIV infection with ritonavir-boosted protease inhibitors in antiretroviral-experienced patients. Am J Health Syst Pharm 2005; 62:809-15.
17. AVANTI and INCAS Study Groups. Highly active antiretroviral therapy including protease inhibitors does not confer a unique CD4 cell benefit. AIDS 2000; 14:1383-8.
18. Podzamczer D, Ferrer E, Consiglio E, et al. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Antivir Ther 2002; 7:81-90.
19. Friedl AC, Ledergerber B, Flepp M, et al. Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. The Swiss HIV Cohort Study. AIDS 2001; 15:1793-800.
20. MacArthur RD, Novak RM, Peng G, et al. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial. Lancet 2006; 368:2125-35.
21. van Leeuwen R, Katlama C, Murphy RL, et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS 2003; 17:987-99.
22. Plana M, Martinez C, Garcia F, et al. Immunologic reconstitution after 1 year of highly active antiretroviral therapy, with or without protease inhibitors. J Acquir Immune Defic Syndr 2002; 29:429-34.
23. Torti C, Maggiolo F, Patroni A, et al. Exploratory analysis for the evaluation of lopinavir/ritonavir- versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER Cohort. J Antimicrob Chemother 2005; 56:190-5.
24. Swiss HIV Cohort Study Web site, 2000. Available at: http://www.shcs.ch/. Accessed 5 September 2008.
25. Ledergerber B, von Overbeck J, Egger M, Luthy R. The Swiss HIV Cohort Study: rationale, organization and selected baseline characteristics. Soz Praventivmed 1994; 39:387-94.
26. Yazdanpanah Y, Sissoko D, Egger M, Mouton Y, Zwahlen M, Chene G. Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect comparison of controlled trials. BMJ 2004; 328:249.
27. Chou R, Fu R, Huffman LH, Korthuis PT. Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses. Lancet 2006; 368:1503-15.
28. Plana M, Ferrer E, Martinez C, et al. Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine. Antivir Ther 2004; 9:197-204.
29. De Luca A, Cozzi-Lepri A, Antinori A, et al. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison. Antivir Ther 2006; 11:609-18.
30. Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004; 36:1011-9.
31. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358:2095-106.
32. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346:2039-46.
33. Kaufmann GR, Furrer H, Ledergerber B, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/ μL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis 2005; 41:361-72.
34. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356:1800-5.